| Primary |
| Benign Prostatic Hyperplasia |
38.2% |
| Hypertension |
18.2% |
| Product Used For Unknown Indication |
12.7% |
| Prostatomegaly |
5.5% |
| Benign Prostatic Hypertrophy |
3.6% |
| Preoperative Care |
3.6% |
| Urinary Tract Disorder |
3.6% |
| Blood Bilirubin Increased |
1.8% |
| Blood Pressure |
1.8% |
| Bph |
1.8% |
| Cardiovascular Disorder |
1.8% |
| Diabetes Mellitus |
1.8% |
| Dysuria |
1.8% |
| Hepatitis Viral |
1.8% |
| Urine Flow Decreased |
1.8% |
|
| Syncope |
18.2% |
| Hypotension |
13.6% |
| Orthostatic Hypotension |
13.6% |
| Dizziness |
9.1% |
| Fall |
6.8% |
| Presyncope |
4.5% |
| Product Quality Issue |
4.5% |
| Blood Glucose Increased |
2.3% |
| Diabetic Ketoacidosis |
2.3% |
| Dyspnoea |
2.3% |
| Grip Strength Decreased |
2.3% |
| Hepatic Function Abnormal |
2.3% |
| Hypersensitivity |
2.3% |
| Iridocele |
2.3% |
| Iris Disorder |
2.3% |
| Loss Of Consciousness |
2.3% |
| Muscle Disorder |
2.3% |
| Overdose |
2.3% |
| Palpitations |
2.3% |
| Product Substitution Issue |
2.3% |
|
| Secondary |
| Drug Use For Unknown Indication |
34.8% |
| Product Used For Unknown Indication |
22.7% |
| Hypertension |
21.2% |
| Benign Prostatic Hyperplasia |
6.1% |
| Coronary Artery Disease |
3.0% |
| Muscle Spasticity |
3.0% |
| Diabetes Mellitus |
1.5% |
| Neoplasm Malignant |
1.5% |
| Pain |
1.5% |
| Preoperative Care |
1.5% |
| Prostatic Disorder |
1.5% |
| Type 2 Diabetes Mellitus |
1.5% |
|
| Syncope |
12.0% |
| Drug Hypersensitivity |
8.0% |
| Organ Failure |
8.0% |
| Pancreatic Carcinoma |
8.0% |
| Arthralgia |
4.0% |
| Choroidal Detachment |
4.0% |
| Diarrhoea |
4.0% |
| Hypertension |
4.0% |
| Infection |
4.0% |
| Multiple Sclerosis |
4.0% |
| Muscular Weakness |
4.0% |
| Nasopharyngitis |
4.0% |
| Nipple Pain |
4.0% |
| Orthostatic Hypotension |
4.0% |
| Pemphigoid |
4.0% |
| Pneumonia |
4.0% |
| Priapism |
4.0% |
| Procedural Pain |
4.0% |
| Product Quality Issue |
4.0% |
| Prostatic Specific Antigen |
4.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.4% |
| Hypertension |
17.7% |
| Drug Use For Unknown Indication |
5.0% |
| Diabetes Mellitus |
4.9% |
| Pain |
4.1% |
| Benign Prostatic Hyperplasia |
3.7% |
| Blood Cholesterol Increased |
3.3% |
| Atrial Fibrillation |
3.3% |
| Cardiac Disorder |
2.5% |
| Gastrooesophageal Reflux Disease |
2.5% |
| Chronic Obstructive Pulmonary Disease |
2.3% |
| Asthma |
2.3% |
| Prostatomegaly |
2.2% |
| Depression |
2.0% |
| Type 2 Diabetes Mellitus |
2.0% |
| Prostatic Disorder |
2.0% |
| Blood Pressure |
1.8% |
| Supplementation Therapy |
1.7% |
| Prophylaxis |
1.7% |
| Rheumatoid Arthritis |
1.7% |
|
| Weight Decreased |
9.5% |
| Drug Ineffective |
7.0% |
| Vision Blurred |
6.0% |
| Vomiting |
6.0% |
| Pain In Extremity |
5.5% |
| Renal Failure Acute |
5.5% |
| White Blood Cell Count Decreased |
5.5% |
| Death |
5.0% |
| Pain |
5.0% |
| Pyrexia |
5.0% |
| Nausea |
4.5% |
| Pneumonia |
4.5% |
| Rash |
4.5% |
| Cerebrovascular Accident |
4.0% |
| Fatigue |
4.0% |
| Speech Disorder |
4.0% |
| Dyspnoea |
3.5% |
| Gastrointestinal Haemorrhage |
3.5% |
| International Normalised Ratio Increased |
3.5% |
| Myocardial Infarction |
3.5% |
|
| Interacting |
| Hypertension |
30.8% |
| Prostatomegaly |
30.8% |
| Benign Prostatic Hyperplasia |
15.4% |
| Rheumatoid Arthritis |
15.4% |
| Erectile Dysfunction |
7.7% |
|
| Nausea |
66.7% |
| Drug Interaction |
33.3% |
|
